Literature DB >> 21871905

Evaluation of urinary biomarkers of oxidative/nitrosative stress in children with Down syndrome.

Carlos Campos1, Rodrigo Guzmán, Encarnación López-Fernández, Angela Casado.   

Abstract

AIMS: It has been suggested that oxidative stress plays a key role in the pathogenesis of Down syndrome (DS). However, urinary biomarkers of oxidative stress have been little studied in this condition. Thus, we aimed to assess a set of urinary oxidative/nitrosative stress biomarkers in children with DS, with and without hypothyroidism, which comprise: 8-hydroxy-2'-deoxyguanosine (8-OHdG), isoprostane 15-F(2t)-IsoP, thiobarbituric acid-reacting substances (TBARS), advanced glycation end products (AGEs), dityrosine (diTyr), hydrogen peroxide (H(2)O(2)) and nitrite/nitrate (NOx). MAIN
METHODS: Fluorimetric and spectrophotometric assays were performed in children with DS (n=26), some of them taking levothyroxine for hypothyroidism (n=7), and their non-Down siblings (n=19). KEY
FINDINGS: We found that only levels of diTyr were increased in DS, although no differences were obtained when hypothyroid DS children were excluded. Levels of 8-OHdG, 15-F(2t)-IsoP, TBARS, AGEs, H(2)O(2) and NOx did not differ neither between DS and controls nor between hypothyroid DS children and DS without hypothyroidism diagnosed. However, diTyr is increased in hypothyroid DS children compared with controls. Negative correlations with age were obtained for 8-OHdG, diTyr and NOx in DS and controls and for 8-OHdG, 15-F(2t)-IsoP, TBARS and AGEs in DS. SIGNIFICANCE: Increased oxidative stress in children with DS cannot be explained by the urinary levels of 8-OHdG, 15-F(2t)-IsoP, TBARS, AGEs, diTyr, H(2)O(2) and NOx, at least with the assays used. Nonetheless, urinary diTyr could be used as oxidative/nitrosative stress biomarker in hypothyroid DS children. The present work presents evidence of a probable renal impairment in children with DS receiving levothyroxine for hypothyroidism.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871905     DOI: 10.1016/j.lfs.2011.08.006

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  How stable is oxidative stress level? An observational study of intra- and inter-individual variability in urinary oxidative stress biomarkers of DNA, proteins, and lipids in healthy individuals.

Authors:  Maria-Pilar Martinez-Moral; Kurunthachalam Kannan
Journal:  Environ Int       Date:  2018-12-17       Impact factor: 9.621

2.  Systemic oxidative stress, as measured by urinary allantoin and F(2)-isoprostanes, is not increased in Down syndrome.

Authors:  Adviye A Tolun; Peter M Scarbrough; Haoyue Zhang; Jane-Ann McKillop; Frances Wang; Priya S Kishnani; David S Millington; Sarah P Young; Dora Il'yasova
Journal:  Ann Epidemiol       Date:  2012-10-11       Impact factor: 3.797

3.  Memory decline in Down syndrome and its relationship to iPF2alpha, a urinary marker of oxidative stress.

Authors:  Panagiotis Zis; Patrick McHugh; Andrew McQuillin; Domenico Praticò; Mark Dickinson; Sima Shende; Zuzana Walker; Andre Strydom
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

Review 4.  Oxidative stress, thyroid dysfunction & Down syndrome.

Authors:  Carlos Campos; Ángela Casado
Journal:  Indian J Med Res       Date:  2015-08       Impact factor: 2.375

5.  Plasma and urinary metabolomic profiles of Down syndrome correlate with alteration of mitochondrial metabolism.

Authors:  Maria Caracausi; Veronica Ghini; Chiara Locatelli; Martina Mericio; Allison Piovesan; Francesca Antonaros; Maria Chiara Pelleri; Lorenza Vitale; Rosa Anna Vacca; Federica Bedetti; Maria Chiara Mimmi; Claudio Luchinat; Paola Turano; Pierluigi Strippoli; Guido Cocchi
Journal:  Sci Rep       Date:  2018-02-14       Impact factor: 4.379

6.  Classifying oxidative stress by F2-isoprostane levels across human diseases: A meta-analysis.

Authors:  Thomas J van 't Erve; Maria B Kadiiska; Stephanie J London; Ronald P Mason
Journal:  Redox Biol       Date:  2017-03-28       Impact factor: 11.799

7.  Nrf2 stabilization prevents critical oxidative damage in Down syndrome cells.

Authors:  Emiliano Zamponi; Nahuel Zamponi; Pinar Coskun; Gonzalo Quassollo; Alfredo Lorenzo; Sergio A Cannas; Gustavo Pigino; Dante R Chialvo; Katheleen Gardiner; Jorge Busciglio; Pablo Helguera
Journal:  Aging Cell       Date:  2018-07-20       Impact factor: 9.304

Review 8.  Adults with Down syndrome challenge another paradigm: When aging no longer entails arterial hypertension.

Authors:  Emilia Roy-Vallejo; José María Galván-Román; Fernando Moldenhauer; Diego Real de Asúa
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-07-09       Impact factor: 3.738

Review 9.  Peripheral Oxidation Markers in Down Syndrome Patients: The Better and the Worse.

Authors:  Dominik Szwajgier; Ewa Baranowska-Wójcik; Joanna Grzelczyk; Wioletta Żukiewicz-Sobczak
Journal:  Dis Markers       Date:  2021-06-28       Impact factor: 3.434

Review 10.  Cancer metabolism and oxidative stress: Insights into carcinogenesis and chemotherapy via the non-dihydrofolate reductase effects of methotrexate.

Authors:  Joshua A Hess; Mohamad K Khasawneh
Journal:  BBA Clin       Date:  2015-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.